retatrutide mechanism triple agonist glp-1 gip glucagon ly3437943 peptide Retatrutide (Triple-Action Jab): Phase III

Furthermore, we developed a highly selective Smurf1 degrader, Smurf1-antagonizing repressor of tumor 1, which exhibits efficient PDK1Akt blockade and potent tumor suppression alone or combined with PDK1 inhibitor in KRAS-mutated CRC

PMID: 16153435

Conditions Locations Treatment Type Trial Phase Trial Status Paid Participation Trial Details Key Eligibility Criteria 450 Participants Needed Trial Details Key Eligibility Criteria 452 Participants Needed Trial Details Key Eligibility Criteria 24 Participants Needed Trial Details Key Eligibility Criteria 350 Participants Needed Trial Details Key Eligibility Criteria 548 Participants Needed Trial Details Key Eligibility Criteria 268 Participants Needed Trial Details Key Eligibility Criteria 100 Participants Needed Trial Details Key Eligibility Criteria 60 Participants Needed Trial Details Key Eligibility Criteria 78 Participants Needed Trial Details Key Eligibility Criteria 150 Participants Needed Trial Details Key Eligibility Criteria 864 Participants Needed Trial Details Key Eligibility Criteria 45 Participants Needed Trial Details Key Eligibility Criteria 20 Participants Needed Trial Details Key Eligibility Criteria 300 Participants Needed Trial Details Key Eligibility Criteria 1000 Participants Needed Trial Details Key Eligibility Criteria 50 Participants Needed Trial Details Key Eligibility Criteria 93 Participants Needed Trial Details Key Eligibility Criteria 89 Participants Needed Trial Details Key Eligibility Criteria 40 Participants Needed Trial Details Key Eligibility Criteria 306 Participants Needed "I have dealt with voice and vocal fold issues related to paralysis for over 12 years

Following that, the frequency changes based on your response

Our awesome team will jump right in and make sure everything is sorted out and accurate for you